Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Long-Term Investments: 2014-2023

Historic Long-Term Investments for ImmunityBio (IBRX) over the last 8 years, with Dec 2023 value amounting to $891,000.

  • ImmunityBio's Long-Term Investments rose 6.07% to $891,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $891,000, marking a year-over-year increase of 6.07%. This contributed to the annual value of $891,000 for FY2023, which is 6.07% up from last year.
  • According to the latest figures from Q4 2023, ImmunityBio's Long-Term Investments is $891,000, which was up 9.06% from $817,000 recorded in Q3 2023.
  • ImmunityBio's Long-Term Investments' 5-year high stood at $9.3 million during Q2 2020, with a 5-year trough of $802,000 in Q3 2021.
  • Moreover, its 3-year median value for Long-Term Investments was $831,000 (2021), whereas its average is $853,750.
  • In the last 5 years, ImmunityBio's Long-Term Investments crashed by 91.38% in 2021 and then rose by 11.19% in 2022.
  • Over the past 5 years, ImmunityBio's Long-Term Investments (Quarterly) stood at $9.3 million in 2019, then dropped by 15.17% to $7.8 million in 2020, then tumbled by 89.53% to $822,000 in 2021, then rose by 2.19% to $840,000 in 2022, then grew by 6.07% to $891,000 in 2023.
  • Its Long-Term Investments stands at $891,000 for Q4 2023, versus $817,000 for Q3 2023 and $841,000 for Q2 2023.